Targeted therapies may promote more decongestion in AHF with cardiorenal syndrome.

This approach to decongestion may not provoke more azotemia than standard care.

Urine output was stable despite previous azotemia and intense diuretic titration.

Target-guided decongestive regimens may be safe and effective in this population.